Site Editors

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement
Advertisement

Published Medical Literature

Cytomorphologic Features of NTRK-Mutated Papillary Thyroid Cancer
First- Versus Second-Generation TRK Inhibitors for NTRK Fusion–Positive Cancers
Next-Generation ROS1/TRK/ALK Inhibitor Under Study in Neuroblastoma
Are NTRK Fusions ‘Bona Fide’ Oncogenic Drivers of Lung Cancer?
Use of Larotrectinib for in Sarcoma of the Chest: Case Study Focused on TMTC2-NTRK3 Fusion
Lipofibromatosis-Like Neural Tumor: Case Featuring an NTRK Abnormality
Case Study: Broad Morphologic Spectrum of Mesenchymal Tumors With NTRK Fusions
Serrated Neoplasia Pathway: A Clue to NTRK-Rearranged Colorectal Tumors
Case Report: Use of FISH Signal Pattern to Confirm Secretory Carcinoma of the Salivary Gland
Pediatric Thyroid Cancer: Should Molecular Subtype Be Included in Risk Stratification?
Multitargeted Treatment Approach to Mammary Analog Secretory Carcinoma: Case Report Focuses on NTRK Fusions
Gene Fusion Testing Strategies for Colorectal, Skin, and Lung Cancers
Larotrectinib for TRK Fusion–Positive Gastrointestinal Cancer
Can NTRK Gene Fusions Influence Chromosomal Imbalances in Soft-Tissue Sarcomas?
TRK Inhibitors for NTRK Fusion–Positive Sarcoma: A Canadian Perspective
Targeting NTRK Gene Fusions in Gliomas
NTRK1-TPM3 Gene Rearrangement in Recurrent Ovarian Cancer: Case Report
How Common Are NTRK Fusions in Bone Tumors in Pediatric Patients?
Rare Case of Mesenchymal Sarcoma With NTRK1 Gene Translocation
European Pediatric Sequencing Programs: Screening for Targetable NTRK Gene Fusions
Differentiated Thyroid Cancer: Molecular Profiling for NTRK Gene Fusions in Assessing Risk for Recurrence
NTRK3 Promoter Methylation: Predictive Marker for Survival in Colorectal Cancer?
Rare Case of Mosaicism in a Glioblastoma Harboring NTRK Fusion and PDGFRA Amplification
Larotrectinib for Pediatric Undifferentiated Sarcoma With an STRN-NTRK2 Fusion: Case Study
Larotrectinib in RAI-Refractory Papillary Thyroid Cancer: Case Report
NTRK Fusion–Positive Solid Tumors: Entrectinib Granted Conditional Marketing Authorization in the European Union
Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?
Case Report: Use of Larotrectinib in a Boy With TRK Fusion–Positive ALL
NTRK Fusions and Cancer: Focus on Biology and Therapeutic Targeting of These Drivers
Shedding Light on the Landscape of NTRK Aberrations in Pediatric and Adult Tumors
Novel TFG‐NTRK2 Fusion in Spitz/Reed Tumor: Case Report
Entrectinib in NTRK Fusion– and ROS1 Fusion–Positive Solid Tumors: Patient-Reported Outcomes
Identifying NTRK Gene Fusions for Targeted Therapy: ‘An Ongoing Clinical Priority’
Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study
Study Identifies Benefits of Testing for NTRK Fusions in Thyroid Cancers
Understanding NTRK Fusion Actionability: An Overview of Targeted Therapy Options
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.